Applicants: Paul Simmons et al.

Serial No.: 10/813,747 Filed : March 29, 2004

Page 3

Listing of Claims:

1-78. (Cancelled)

- 79. (New) A method of generating a tissue in a subject comprising administering to the subject a population of cells enriched for STRO-1^{bright} cells, wherein such STRO-1^{bright} cells are mesenchymal precursor cells which comprise mesenchymal precursor cells capable of giving rise to colony forming unit-fibroblasts (CFU-F) so as to generate the tissue in the subject.
- 80. (New) The method of claim 79, wherein the tissue is a mesenchymal tissue.
- 81. (New) The method of claim 80, wherein the mesenchymal tissue is smooth muscle, cardiac muscle or endothelial tissue.
- 82. (New) The method of claim 79, wherein the tissue is non-haemopoietic tissue.
- 83. (New) The method of claim 82, wherein the tissue is adipose, areolar, bone, cartilaginous, elastic, or fibrous connective tissue.
- 84. (New) The method of claim 79, wherein the mesenchymal precursor cells carry at least one additional marker selected from the group of surface markers consisting of THY-1, VCAM-1, STRO-2, and CD146.
- 85. (New) The method of claim 84, wherein the mesenchymal precursor cells carry the markers STRO-1 and VCAM-1.

Applicants: Paul Simmons et al.

Serial No.: 10/813,747 Filed : March 29, 2004

Page 4

- 86. (New) The method of claim 79, wherein said STRO-1^{bright} cells in the enriched population comprise an exogenous nucleic acid that expresses a therapeutic agent.
- 87. (New) The method of claim 79, wherein the tissue is bone marrow.
- 88. (New) The method of claim 87, wherein the population of cells is preadsorbed onto a ceramic vehicle that is precoated with fibronectin and is implanted to augment bone marrow transplantation.
- 89. (New) The method of claim 88, which further comprises administering haemopoietic cells to the subject.
- 90. (New) The method of claim 79, wherein the STRO-1 pright cells are negative for at least one marker selected from the group consisting of CBFA-1, collagen type II, PPAR γ 2, and glycophorin A.